Dr. Fred R. Hirsch Addresses Unmet Needs in Lung Cancer Treatment
Speaking in an interview with Oncology Nursing News, Dr. Fred R. Hirsch, CEO of IASLC, Professor of Medicine and Pathology at the University of Colorado, discusses the importance of combination therapies in the fight against lung cancer. Noting progress in single agent therapy, Dr. Hirsch points out the challenge of finding the best combination of therapies to take treatment to the next level.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization specifically dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 4,000 lung cancer specialists in more than 90 countries. For more information, visit: https://www.iaslc.org/.